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Background. The live attenuated vaccine Zostavax was developed to prevent varicella zoster virus (VZV) reactivation that causes 
herpes zoster (shingles) in older humans. However, the impact of vaccination on the cutaneous response to VZV is not known.
Methods. We investigated the response to intradermal VZV antigen challenge before and after Zostavax vaccination in partici-
pants >70 years of age by immunohistological and transcriptomic analyses of skin biopsy specimens collected from the challenge site.
Results. Vaccination increased the proportion of VZV-specific CD4+ T cells in the blood and promoted the accumulation of both 
CD4+ and CD8+ T cells in the skin after VZV antigen challenge. However, Zostavax did not alter the proportion of resident memory 
T cells (CD4+ and CD8+) or CD4+Foxp3+ regulatory T cells in unchallenged skin. After vaccination, there was increased cutaneous 
T-cell proliferation at the challenge site and also increased recruitment of T cells from the blood, as indicated by an elevated T-cell 
migratory gene signature. CD8+ T-cell–associated functional genes were also highly induced in the skin after vaccination.
Conclusion. Zostavax vaccination does not alter the abundance of cutaneous resident memory T cells but instead increases the 
recruitment of VZV-specific T cells from the blood and enhances T-cell activation, particularly cells of the CD8+ subset, in the skin 
after VZV antigen challenge.
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Older individuals show reduced immune function, leading to 
an increased incidence of infection and malignancy [1, 2]. The 
increased susceptibility to infection in this population is compli-
cated by less robust immunological responses to vaccination [3]. 
As the number of people in the world aged 60 years and over 
will almost triple to 2 billion by 2050, the consequences for 
infection-related morbidity and mortality and the resource 
implications for healthcare delivery are profound.
Varicella zoster virus (VZV) causes the primary infection 
varicella (or chickenpox). Following resolution of the primary 
infection, the virus maintains lifelong latency in dorsal root 
ganglia. Reactivation of VZV, known as herpes zoster (HZ) 
or shingles, is associated with age- or disease-induced wan-
ing of VZV-specific cellular immunity [4–6]. While it is clear 
that T-cell–mediated immunity plays a crucial role in immune 
protection against reactivation of VZV, as indicated by an 
increased incidence of HZ in immunosuppressed individuals 
[6, 7], the mechanisms of this protection have not been eluci-
dated. Cutaneous T-cell immune responses to intradermal VZV 
antigen challenge are considered to reflect the status of an indi-
vidual’s immune response to this pathogen [8, 9]. A weak skin 
immune response to VZV antigen challenge is associated with a 
greater susceptibility to HZ and postherpetic neuralgia [10, 11]. 
Cutaneous immunity is observed to wane with increased 
age [12], but the mechanisms responsible for this decline are 
unknown; it is also unclear whether the deterioration in skin 
immunity is responsible for the lack of protection against VZV 
reactivation during aging.
The live attenuated shingles vaccine, with the proprietary 
name of Zostavax, was developed to prevent HZ in older indi-
viduals [13]. The vaccine has been shown to boost the robust-
ness of circulating VZV-specific CD4+ T-cell responses and 
VZV-specific antibody production, but its effects on VZV-
specific T cells in the skin are not known [14, 15]. As the skin is 
the first site to which the virus migrates after reactivation in the 
dorsal root ganglia [16], we sought to elucidate how Zostavax 
vaccination alters immune cell populations resident within 
the skin.
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We previously developed an experimental system to inves-
tigate antigen-specific immunity in vivo, whereby healthy 
volunteers are challenged intradermally with a recall antigen 
to induce an antigen-specific delayed-type hypersensitivity 
response [17]. Using this experimental system, we identified 
that older humans (age, >65 years) demonstrate decreased cuta-
neous immune responses to VZV antigen challenge [12]. In 
this current study, we investigated the impact of Zostavax vac-
cination on cutaneous immunity to VZV in older individuals. 
A cohort of volunteers aged >70 years was recruited, and their 
responses to VZV antigen challenge were assessed before and 
after vaccination. We show that, although vaccination increased 
the proportion of VZV-specific CD4+ T cells in the blood, the 
proportion of these cells within the skin (ie, skin-resident mem-
ory T cells [TRM]) was not affected. Vaccination also enhanced 
the skin response to VZV antigen challenge and was associated 
with increased T-cell accumulation and proliferation at the site 
of antigen challenge. After vaccination, there was a marked 
upregulation of genes associated with migration and activation 
of T cells at the site of antigen challenge. Additionally, there was 
a pronounced expression of a CD8+ T-cell–related gene signa-
ture in the skin after VZV antigen challenge in vaccinated indi-
viduals. Taken together, these data suggest that the improved 
VZV-specific cutaneous immunity after Zostavax vaccination is 
due to the recruitment of VZV-specific T cells from the blood 
that are then activated and induced to proliferate in the skin.
MATERIALS AND METHODS
This work was approved by the Ethics Committee of Queen’s 
Square (London) and by the Institutional Review Board of the 
University College London Research and Development Office. 
We recruited 122 healthy older individuals (age, >70  years; 
median age, 75 years; 77 women and 45 men) and 108 healthy 
young individuals (age, <40  years; median age, 28  years; 60 
women and 48 men) into the study investigating the effects of 
age on immunity to VZV.
For the vaccination study, we recruited a subset of 30 healthy 
older individuals aged >70  years (age range, 70–93  years; 
median age, 75.5 years; 10 men and 20 women). Following the 
initial VZV skin antigen challenge, Zostavax was administered 
as per the manufacturer’s instructions to individuals whose 
clinical score was ≤4. Between 2 and 6 months later, VZV anti-
gen challenge was repeated, as depicted in the schematic repre-
sentation of the study in Figure 1C. Individuals with a history of 
neoplasia, immunosuppressive disorders, or inflammatory skin 
disorders were excluded from this investigation. Furthermore, 
we excluded individuals with comorbidities that are associated 
with significant internal organ or immune dysfunction, includ-
ing heart failure, severe chronic obstructive pulmonary disease, 
diabetes mellitus, and rheumatoid arthritis. We also excluded 
individuals receiving immunosuppressive regimens for the 
treatment of autoimmune or chronic inflammatory diseases (eg, 
oral glucocorticoids, methotrexate, azathioprine, and cyclospo-
rine). However, we did not exclude older individuals who take 
aspirin, nonsteroidal antiinflammatory drugs, statins, and anti-
hypertensive agents, owing to the widespread use of these drugs 
in this age group. All volunteers provided written, informed 
consent, and study procedures were performed in accordance 
with the principles of the Declaration of Helsinki.
Skin Tests
VZV antigen (Biken, The Research Foundation for Microbial 
Diseases of Osaka University, Japan) was injected intradermally 
into the sun-protected skin of the medial proximal volar forearm as 
per the manufacturer’s instructions. Induration, palpability, and the 
change in erythema from baseline were measured and scored on day 
3 as described previously [17]. A clinical score (range, 0–10) based 
on the summation of these parameters was then calculated [17]. 
Older individuals with a clinical score >4 were excluded from 
further participation, as such individuals showed characteristics 
of cellular infiltration and responsiveness indistinguishable from 
those observed in young volunteers [8, 18].
Skin Biopsy Specimens
For immunofluorescence experiments, punch biopsy specimens 
(5 mm in diameter) from the site of VZV antigen challenge were 
obtained at various time points (as indicated) after injection. 
Control skin punch biopsy specimens from normal (unchal-
lenged) forearm skin were also obtained. Biopsy specimens 
were frozen in optimal cutting temperature compound (Bright 
Instruments). Six-micrometer sections were cut, left to dry over-
night, fixed in ethanol and acetone, and stored at −80°C.
Immunofluorescence
Sections were stained with optimal dilutions of primary anti-
bodies, followed by an appropriate secondary antibody conju-
gated to various fluorochromes as described elsewhere [8, 12] 
(Table 1).
Activated endothelium images were acquired on the 
AxioScan Z1 slide scanner and analyzed on Zen Blue (Zeiss, 
Cambridge, United Kingdom). All other images were acquired 
using appropriate filters of a Leica DMLB microscope with a 
Leica N PLAN 20×/0.40 objective and a Cool SNAP-Pro cf 
Monochrome Media Cybernetics camera, controlled by Image-
Pro Plus 6.2 software. When counting the numbers of cells in 
perivascular infiltrates, the 5 largest perivascular infiltrates 
present in the upper and mid-dermis were selected for analy-
sis, and an average was calculated as described previously [19].
Peripheral Blood Mononuclear Cell (PBMC) Preparation and Skin Biopsy 
Specimen Digestion
Heparinized blood samples were collected from volunteers at 
the time of VZV antigen challenge. PBMCs were prepared by 
density centrifugation on Ficoll-Paque (Amersham Biosciences, 
Little Chalfont, UK) and resuspended in complete medium.
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Skin biopsy specimens (5  mm in diameter) were collected 
from unchallenged skin and disaggregated by overnight incu-
bation (37°C; 5% CO2) in 0.8  mg/mL collagenase IV (Sigma 
Aldrich) with 20% fetal calf serum. Single-cell suspensions 
were obtained by filtering the suspension through 100-, 70-, 
and 40-µm filters.
Flow Cytometric Analysis
PBMCs or skin-derived leukocytes were stimulated with 40 μL/
mL VZV lysate (Virusys, Taneytown, MD) or 1  μL/mL SEB 
as a positive control and were incubated for 15 hours at 37°C 
and 5% CO2 in the presence of 5 µg/mL brefeldin A  (Sigma-
Aldrich, Gillingham, UK). Following stimulation, cells were 
stained using combinations of antibodies, including CD3 
(clone UCHT1), CD4 (RPA-T4), and CD8 (SK1), for 30 min-
utes at 4°C and washed, fixed, and permeabilized (Fix & Perm 
Cell Permeabilisation Kit, Invitrogen, Paisley, UK) before 
staining for interleukin 2 (clone 5344.111), interferon γ (IFN-
γ; B27), and tumor necrosis factor α (TNF-α; Mab11; all from 
BD Biosciences, Oxford, UK). Multiparameter investigation of 
skin and blood T-cell phenotypes was performed on an LSR 
II or BD Fortessa instrument, using FACS Diva software (BD 
Biosciences, Oxford, UK), and data were subsequently analyzed 
using FlowJo, version X (TreeStar, Ashland, OR), as previously 
described [12, 19].
Transcriptional Analysis
Punch biopsy specimens (3  mm in diameter) were collected 
from the VZV antigen challenge site (6 or 72 hours after injec-
tion), immediately frozen in RNAlater, and stored at −20°C until 
use. Unchallenged forearm skin was collected as a control from 
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Figure 1. Zostavax vaccination improves cutaneous response to varicella zoster virus (VZV) antigen challenge in older individuals. A, Healthy young (n = 108) and older 
(n = 122) volunteers were injected with 0.02 mL of VZV skin antigen test. A clinical score at day 3 was calculated based on induration, palpability, and redness. B, Proportion 
of VZV-specific CD4+ T cells (defined as being positive for interferon γ [IFN-γ+] after overnight stimulation with VZV lysate) in peripheral blood of young and older volunteers 
(n = 104; 55 young, 12 middle-aged, and 37 older adults). C, Schematic representation of the study to investigate the effects of Zostavax on VZV antigen challenge in older 
individuals (n = 30). D, Change in day 3 clinical score before and after vaccination. For panels A and D, data were assessed by Mann-Whitney and Wilcoxon paired tests, 
respectively. For panel B, data were assessed by a Pearson correlation test.
Table 1. List of Antibodies Used for Immunofluorescence
Antibody name Clone Company
CD4 SK3 or YNB46.1.8 BD Bioscience
CD8 RPA-T8 BD Bioscience
Ki67-FITC B56 BD Bioscience
CD31-FITC WM59 BD Bioscience
CD69 FN50 Biolegend
CD103 2G5.1 Thermofisher
Foxp3-biotin PCH101 eBioscience
E-selectin ENA1 Abcam
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a number of volunteers. Frozen tissue specimens were homog-
enized, and total RNA was extracted from bulk tissue homoge-
nates, using the RNeasy Mini Kit (Qiagen). Target amplification 
and labeling were performed according to standard protocols, 
using the Nugen Ovation WB Kit. RNA was hybridized to 
Affymetrix Human Genome U133 2.0 plus arrays. Affymetrix 
gene chips were scanned for spatial artifacts, using the Hirshlight 
package [20]. Gene expression measures were obtained using the 
GCRMA algorithm [21]. Gene expression was modeled using 
mixed models in R’s limma framework, which accounts for the 
within-patient correlation structure, and batch effect was elim-
inated using linear models. Differences between groups were 
estimated from this model and its significance assessed using 
the moderated (paired/unpaired) t test. Resulting P values 
were adjusted for multiple hypotheses, using the Benjamini-
Hochberg procedure. Gene set variation analysis was used to 
obtain the per-pathway scores for each patient and sample, using 
a collection of skin-specific pathways curated by the laboratory 
of J.  K.  and extensively used in publications [21–23] and the 
collection of canonical pathways from the Molecular Signatures 
database (MSigDB; available at: http://software.broadinstitute.
org/gsea/msigdb/). Pathway scores were then analyzed with the 
same approach as the gene-based analysis.
Statistics
Statistical analysis was performed using GraphPad Prism, 
version 6.00 (GraphPad Software, San Diego, CA). Paired or 
unpaired t tests were used when data were normally distributed; 
otherwise, nonparametric tests were used. The Kruskal-Wallis 
test was used to compare ≥3 unpaired groups, and a 2-tailed 
Mann-Whitney test was used when comparing only 2 unpaired 
groups. The Wilcoxon matched pairs test was used when com-
paring 2 groups of matched data.
RESULTS
Decreased Cutaneous Response to VZV Antigen Challenge in Older 
Individuals Can Be Boosted by Zostavax Vaccination
We confirmed previous observations that older individuals 
(n = 122; age, >70 years; age range, 70–92 years; 45 men and 77 
women) have decreased cutaneous responsiveness to VZV anti-
gen challenge when compared to younger individuals (n = 108; 
age, <40 years; age, range, 20–39 years; 48 men and 60 women; 
Figure 1A) [12, 22]. We also confirmed previous findings of a 
decreased proportion of VZV-specific CD4+ T cells in the cir-
culation during aging (Figure 1B); VZV-specific CD4+ T cells 
were defined as IFN-γ–producing leukocytes, after overnight 
stimulation with VZV lysate in vitro [8, 23].
To investigate the effects of Zostavax on cell-mediated 
immunity to VZV, we designed a study to compare cutane-
ous responses in older individuals before and after vaccination 
(Figure  1C). VZV antigen challenge was performed before 
and after vaccination, and the clinical score was calculated at 
72 hours, as described previously [17]. Of 30 volunteers who 
consented to the study, 5 had a starting score of 4, reflecting a 
moderate response; none of these 5 received a boost in clinical 
response after vaccination.
Further analysis was performed on the remaining 25 volun-
teers who had a starting clinical score ≤3. Nineteen of 25 (76%) 
had an enhanced clinical response after vaccination, whereas 
the remaining individuals (24%) showed no improvement. As 
a group, there was a significant increase in clinical score after 
vaccination, from a median score of 1 before vaccination to a 
median score of 3 after vaccination (P < .0001; Figure 1D). In 
parallel studies, we showed that the rechallenge of older volun-
teers with VZV skin test antigen at intervals of 2–3 months did 
not by itself boost their original clinical score [18].
Effect of Zostavax Vaccination on Skin-Resident Memory T Cells
Tissue-resident memory T cells (TRM) in the skin and other tis-
sues can be identified by the expression of CD69 [8, 24, 25]. 
Zostavax vaccination had no effect on the proportions of cuta-
neous TRM in unchallenged skin, in either CD4+ (Figure  2A) 
or CD8+ T-cell subsets (Figure  2B). In addition, TRM can be 
further subdivided by their relative expression of CD103 [26], 
but there were also no differences in T-cell CD103 expres-
sion before and after Zostavax vaccination (data not shown). 
As reported previously, older individuals have increased pro-
portions of CD4+Foxp3+ regulatory T cells (Tregs) in the 
skin as compared to young individuals [19] (Figure  2C, 2D). 
However, Zostavax vaccination did not alter the proportions of 
these cells in unchallenged skin (Figure 2D).
We next investigated the impact of Zostavax vaccination on 
skin and peripheral blood VZV-specific CD4+ T cells. There 
was a significant increase in the proportion of IFN-γ–produc-
ing VZV-specific CD4+ T cells in the blood after vaccination 
(P = .027), confirming previous results [15, 27, 28]. In contrast, 
there was no increase in the proportion of VZV-specific CD4+ T 
cells in unchallenged skin after vaccination (Figure 2E).
Enhanced Responsiveness to VZV Antigen Challenge After Zostavax 
Vaccination
To investigate how Zostavax vaccination altered the kinetics of 
the VZV-specific immune response in the skin, punch biopsy 
specimens were collected at the site of VZV antigen challenge 
at days 3 and 7 after injection, before and after vaccination, 
and the numbers of CD4+ and CD8+ T cells in the skin were 
quantified by immunohistological assessment. The 5 larg-
est perivascular infiltrates in the mid-dermis and upper der-
mis were chosen and the mean number of leukocytes within 
them calculated. We previously showed that, on days 3 and 7 
following VZV antigen challenge, there were reduced num-
bers of CD4+ T cells present at the challenge site in older as 
compared to young volunteers [12]. In the current study, we 
found that, following Zostavax vaccination, older individuals 
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had significantly increased numbers of both CD4+ T cells 
(Figure 3A) and CD8+ T cells (Figure 3B) in the skin after VZV 
antigen challenge. There was a significant correlation between 
the increase in clinical score after vaccination and the abun-
dance of CD4+ T cells in the skin (Figure 3C). Furthermore, 
there was increased activation of endothelial loops (identified 
as CD31+ E-selectin–positive cells [29]) in the skin at the site 
of VZV antigen challenge after vaccination (Figure 3D), which 
was also significantly associated with the increase in clinical 
score after vaccination.
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Figure 2. Zostavax vaccination leads to an increase in circulating but not skin-resident varicella zoster virus (VZV)–specific T cells. Punch biopsy specimens (diameter, 
5 mm) were taken from unchallenged skin before and after vaccination and immunohistological assessment was performed. A and B, Frequency of CD4+ (A) and CD8+ (B) T 
cells that expressed CD69. C and D, Representative immunostaining of CD4 (green) and Foxp3 (red; C) and cumulative data showing the frequency of Foxp3+ CD4+ T cells (D) 
in young and older individuals (before and after vaccination). E, Peripheral blood and skin-derived VZV-specific CD4+ T cells were enumerated by intracellular cytokine staining 
following overnight stimulation with VZV lysate (n = 6 for skin and n = 10 for blood). For panels A and B, data were assessed by the Mann-Whitney test. For panel D, data 
were assessed by 1-way analysis of variance with the Tukey post hoc test. For panel E, data were analyzed by the Wilcoxon paired test. Abbreviation: NS, not significant. 
*P < .05 and **P < .01.
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Increased T-Cell Proliferation After Zostavax Vaccination in VZV 
Antigen–Challenged Skin
Subsequently, we investigated whether the increased T-cell accu-
mulation in VZV antigen–challenged skin after Zostavax vac-
cination was due in part to local proliferation at the challenged 
site. To do this, we compared the expression of Ki67 within 
CD4+ and CD8+ T cells in skin biopsy specimens collected at 
3 and 7  days from the site of VZV antigen challenge. There 
was a trend toward an increase in proliferation in the CD4+ 
T-cell population that was not significant (Figure 4A and 4B). 
However, there was a significant increase in CD8+ T-cell prolifer-
ation at both 3 and 7 days after VZV antigen challenge in the skin 
of individuals who had received the Zostavax vaccine (Figure 4A 
and 4C). This suggests that, in addition to recruitment from the 
blood, Zostavax vaccination increases the proliferation of T cells, 
especially the CD8+ subset, at the site of VZV antigen challenge, 
which contributes to increased T-cell accumulation.
Although the frequency of  Foxp3+ Tregs was unal-
tered in unchallenged skin after Zostavax vaccination 
(Figure  2C and 2D), the proportion of Foxp3+ Tregs sig-
nificantly decreased at the site of VZV antigen chal-
lenge after vaccination when compared to prevaccination 
VZV antigen challenge responses (Figure  4D and 4E). 
This was not due to an absolute decrease in Treg numbers but 
instead was due to an increase in the non-Treg CD4+ T-cell 
population. This suggests that Tregs either proliferate to a lesser 
extent in the skin than conventional T cells or are not recruited 
to the same extent from the blood after vaccination.
Transcriptional Analysis After Zostavax Vaccination
We next performed global gene expression analyses to identify 
genes that may be associated with the improved response to VZV 
antigen challenge following vaccination. For each donor, skin 
punch biopsy specimens were collected from the site of VZV anti-
gen challenge (at 6 hours and 72 hours after challenge), both before 
and after Zostavax vaccination. The gene expression was com-
pared to that in biopsy specimens collected from unchallenged 
skin. In a previous study, we showed that, in unchallenged skin, 
there was little difference in gene expression between young and 
older age groups [8]. Six hours after VZV antigen challenge, there 
was a relatively minor difference in the numbers of differentially 
expressed genes (DEGs) before and after Zostavax vaccination 
(Figure 5A and 5B and Supplementary Table 1). Genes associated 
with migration (eg, SELL, CXCL10, SELE, ICAM1, and IL8) were 
among the most upregulated genes in both prevaccination and 
postvaccination groups as compared to findings in unchallenged 
skin biopsy specimens, although expression was relatively higher 
after vaccination (Supplementary Tables 1 and 2).
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Figure 3. Zostavax vaccination leads to an increase in T-cell accumulation at the site of varicella zoster virus (VZV) antigen challenge. Punch biopsy specimens (diameter, 
5 mm) were obtained on days 3 and 7 after VZV antigen challenge, before and after vaccination. A and B, Cumulative data showing number of CD4+ (A) and CD8+ (B) T cells 
per perivascular (PV) infiltrate before (black) and after (gray) vaccination on days 3 and 7 after VZV antigen challenge. C, Correlation between change in CD4+ (left) and CD8+ 
(right) T-cell number and change in clinical score after vaccine administration. D, Correlation between change in activated endothelium (calculated as the percentage of CD31+ 
loops expressing E-selectin) and change in clinical score after vaccine administration. For panels A and B, data were assessed by the Mann-Whitney test. For panels C and 
D, data were assessed by the Pearson correlation test.
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At 72 hours after VZV antigen challenge, Zostavax vacci-
nation led to a strong transcriptional response that was con-
siderably more pronounced than the 72-hour transcriptional 
response before vaccination (>5000 DEGs after vaccination 
[false-discovery rate  of <0.05; fold change of >2], compared 
with 1711 DEGs before vaccination Figure 5A and 5B). The top 
30 significantly DEG following Zostavax vaccination are shown 
in Figure 6A, indicating that the same genes were upregulated 
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7 after VZV antigen challenge, before and after vaccination. A, Representative images showing the frequency of CD4+ (top; red) and CD8+ (bottom; red) T cells expressing 
Ki67 (green) before and after vaccination. Cumulative data showing the frequency of proliferating CD4+ (B) and CD8+ (C) T cells, before (black) and after (gray) vaccination. D 
and E, Representative images of CD4 (green) and Foxp3 (red; D) and cumulative data showing the frequency of CD4+ T cells that were Foxp3+ before (black) and after (gray; E) 
vaccination. Data represent a mixture of paired and unpaired samples and were assessed by the Mann-Whitney test. *P < .05.
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72 hours after VZV antigen challenge but to a significantly 
higher extent following vaccination. Genes associated with 
migration (CXCL10, CXCL9, SELL, CCL5, and ITGAL) and 
T-cell and dendritic cell activation, including ITGAX (which 
encodes CD11c), CD2, CD28, CD69, EOMES, ICOS, STAT1, and 
GZMB, were more highly expressed in the skin 72 hours after 
VZV antigen challenge in vaccinated individuals as compared 
to unvaccinated individuals (Figure 6A). This supports the his-
tological observations of an increase in T-cell accumulation in 
VZV-challenged skin after vaccination (Figure  3). These data 
also showed marked upregulation of genes involved in signaling 
pathways associated with innate immune responses, inflamma-
tion, antiviral immune responses, and inflammatory cytokine 
signaling (type I IFN, TNF-α, and IFN-γ) in vaccinated older 
individuals (Figure 6B). Of interest, many genes associated with 
the activity of CD8+ cytotoxic T cells, including GZMB, GNLY, 
GZMA, and CD8A, were highly induced in vaccinated individ-
uals, coinciding with the significantly increased CD8+ T-cell 
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Figure 5. Transcriptomic analysis of varicella zoster virus (VZV) antigen-challenged skin before and after Zostavax vaccination. Punch biopsy specimens (diameter, 3 mm) 
were collected from older individuals before and after vaccination at 6 and 72 hours after VZV antigen challenge (n = 9 before; n = 7 after). Unchallenged skin punch biopsy 
specimens were collected from an additional group of volunteers (n = 6). Total skin RNA was isolated, amplified, and hybridized to Affymetrix Human Genome U133 2.0 plus 
arrays. A, Heatmap showing the relative expression of differentially expressed genes (DEGs) between VZV antigen–challenged and normal unchallenged skin before (left 
panel) and after (right panel) vaccination at a fold change of >2 and a false-discovery rate of >0.05. (B) Venn diagrams showing numbers of DEGs at 6 hours (top) and 72 hours 
(bottom) following VZV antigen challenge, compared with normal unchallenged skin. Upregulated genes are shown in red, and downregulated genes are shown in blue.
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proliferation at the site of VZV antigen challenge at 72 hours 
(Figure 4C). This indicates that Zostavax vaccination enhances 
the activity of VZV-specific CD8+ T cells in the skin.
DISCUSSION
The impact of Zostavax vaccination on immunity has typically 
been assessed by the measurement of anti-VZV antibody lev-
els or changes in VZV-specific T cells in the circulation [13, 27, 
30]. Although the morbidity associated with VZV reactivation is 
associated with the skin, there is little information on the effect 
of this vaccine on cutaneous immunity. We confirmed findings 
from previous studies showing that vaccination of older volun-
teers led to a significant improvement in the cutaneous immune 
response to VZV [22, 31, 32]. However, using histological and 
transcriptomic analyses, we extended these observations by 
characterizing changes in immune cell populations at the cuta-
neous site of VZV antigen challenge. The first conclusion from 
our study is that Zostavax vaccination did not, on its own, have 
a direct impact on the frequency of VZV-specific CD4+ TRM in 
the skin. However, as reported previously, increases in the pro-
portion of VZV-specific CD4+ T cells in the circulation were 
observed [27]. Therefore, Zostavax vaccination protects against 
HZ by a mechanism that does not involve a direct increase in 
the frequency of VZV-specific CD4+ TRM in the skin. It is pos-
sible, however, that the function of VZV-specific TRM may be 
enhanced by vaccination, either by direct immune boosting or by 
a dynamic equilibrium between recently activated VZV-specific 
T cells in the blood and the VZV-specific TRM populations.
Zostavax boosted the clinical response to VZV antigen chal-
lenge in older individuals, and this correlated with increased 
endothelial activation and enhanced CD4+ T-cell accumulation 
in VZV antigen–challenged skin. These findings support our 
data from young individuals, in whom VZV antigen challenge 
resulted in early endothelial activation beginning 6 hours after 
challenge and peaking by 24 hours, while T-cell accumula-
tion was observed by day 3 and peaked around day 7 [12, 18]. 
Collectively, these data suggest that, in vaccinated older indi-
viduals, the improvement in clinical response to VZV antigen 
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Figure 6. Pathways upregulated in the skin after Zostavax vaccination. A, Table showing the top 30 genes upregulated at 72 hours after varicella zoster virus (VZV) 
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intensity represents the strength of the dysregulation determined by the FDR.
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challenge is dependent on an enhancement in early endothelial 
activation, which leads to increased T-cell recruitment to the 
challenged site.
Previous studies have reported an increase in Foxp3+ 
Tregs in normal unchallenged skin during aging [12, 19, 33]. 
Furthermore, in aging individuals there is a highly significant 
correlation between an increased proportion of Tregs in the skin 
and decreased immune responses to VZV antigen challenge [12]. 
It is likely that the increased proportion of Tregs in skin may 
hinder the activation of TRM during VZV antigen challenge 
in older individuals. During the time course of a cutaneous 
immune response to VZV antigen challenge in young indi-
viduals, the numbers of CD4+ Tregs increased in parallel with 
conventional CD4+ T cells so that the proportions of these cells 
within the CD4+ compartment remained relatively stable [19]. 
In contrast, after Zostavax vaccination the proportion of CD4+ 
Tregs in the skin decreased significantly, which may explain 
why the cutaneous immune response to VZV antigen challenge 
increased in vaccinated individuals. However, the total number 
of Tregs was relatively unchanged in VZV-challenged skin after 
Zostavax vaccination, suggesting that either the rate of prolif-
eration of Tregs in the skin is lower than that of conventional T 
cells or that conventional T cells are preferentially recruited from 
the circulation. It is unlikely that Foxp3 in this case represents a 
marker of activated cells, as our previous work has shown that 
these Foxp3+ cells are suppressive [19]; furthermore, there is no 
significant overlap in the expression of Foxp3 and the prolifer-
ation marker Ki67. One hypothesis is that, since Zostavax vac-
cination increases the proportion of VZV-specific CD4+ T cells 
in the blood, the recruitment of these cells into the skin during 
VZV antigen challenge amplifies the immune response, induces 
optimal endothelial activation, and overrides the inhibitory 
influence of the cutaneous Treg populations in older individuals.
Another conclusion is that Zostavax vaccination induces 
a strong CD8+ cytotoxic T-cell–related gene signature in the 
skin after VZV antigen challenge, which occurs in parallel with 
CD8+ T-cell proliferation in situ. In a previous study, while cir-
culating CD4+ T-cell responses were observed in response to 
multiple VZV antigens, only ORF-9 induced significant CD8+ 
T-cell responses. Zostavax vaccination led to 2.8-fold and 4.9-
fold increases in the frequency of ORF-9–specific CD8+ T cells 
producing IFN-γ and TNF-α, respectively [15]. The enhanced 
CD8+ T-cell signature in the skin after VZV antigen challenge in 
vaccinated older individuals indicates that it will be important 
to determine the specificity of these cells and their role in the 
protection against HZ.
Finally, a new VZV glycoprotein E subunit vaccine (Shingrix) 
has been developed that provides >97% protection against the 
development of HZ in older individuals [34], which compares 
highly favorably to Zostavax, which was only 37.6% effective in 
individuals aged >70 years [13]. It will be of considerable inter-
est to determine the impact of Shingrix on cutaneous immunity 
after VZV antigen challenge, especially on the CD8+ T-cell 
compartment, and to compare the transcriptional response in 
VZV-challenged skin after Shingrix vaccination to that induced 
by Zostavax. This may identify correlates of immune enhance-
ment and pathways that may be manipulated to boost immunity 
during aging.
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